| http://www.w3.org/ns/prov#value | - Detailed Description Based on this, the ISS T-003 study in South Africa was started; the study is a phase II, randomized, double-blinded, placebo controlled, clinical trial to evaluate (as a primary end-point) and the safety (as a secondary end-point), of a therapeutic, recombinant, biologically active HIV-1 Tat vaccine in HIV-1 infected, anti-Tat antibody negative, ARV-treated adult volunteers wi
|
